MAIA

#4008
MAIA Biotechnology, Inc. Common Stock
1.3 8 USD
+0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.36
1.39
Intervallo Annuale
1.16
2.46
Variazione giornaliera
+5.34%
Variazione Mensile
+5.34%
Variazione di 6 mesi
-8.91%
Variazione Annuale
-33.65%
Chiusura Precedente
1.3 1
Open
1.3 8
Minimo
1.3 6
Massimo
1.3 9
Volume
116
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q3 FY2025

Full document

MAIA Biotechnology, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on July 28, 2025. The company is incorporated in Delaware and its common stock trades on the NYSE American. MAIA is designated as an emerging growth company.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance data.

Material Changes

On July 28, 2025, the company announced that the U.S. Food and Drug Administration (FDA) granted fast-track designation for Ateganosine. This designation is for the treatment of non-small cell lung cancer (NSCLC).

Guidance, Outlook, and Risks

The filing includes standard forward-looking statements regarding the company's research and development programs. Management highlighted several risks that could cause actual results to differ from expectations, including:

  • The initiation, timing, cost, progress, and results of preclinical and clinical studies.
  • The ability to advance product candidates into and successfully complete clinical studies.
  • The timing or likelihood of regulatory filings and approvals.
  • The ability to develop, manufacture, and commercialize product candidates.
  • Market acceptance and the size of potential markets.
  • The ability to obtain and maintain intellectual property protection.

The company explicitly states it undertakes no obligation to update forward-looking statements except as required by law.

Investor Verification Checklist

  • Verify the specific criteria met for the FDA fast-track designation for Ateganosine in the attached press release (Exhibit 99.1).
  • Confirm the current clinical development stage of Ateganosine for non-small cell lung cancer.
  • Review the company's most recent 10-Q or 10-K for up-to-date cash runway and burn rate, as this 8-K does not contain financial data.
  • Assess the timeline for potential regulatory filings following the fast-track designation.

Notizie